IP Library Granted Patent US 10,286,043
Granted Patent B2
US 10,286,043 · App. 15/544,960 · Granted May 14, 2019

Collagen III composition and uses

Inventor: Susan Volk (Media, PA)
Assignee: The Trustees of the University of Pennsylvania
A61K38/39A61K9/0024A61K9/06A61K9/70A61K47/10A61K47/34C07K14/78D01F4/00D01F6/625D01F6/66D10B2509/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,286,043
App. No.
15/544,960
Granted
May 14, 2019
Kind
B2
Abstract

The invention includes methods of suppressing cancer metastasis and local recurrence in a subject. In one aspect, the method comprises removing the tumor by surgery; and implanting a composition of the invention to the site of the primary tumor. In another aspect, the method comprises implanting a composition of the invention to a cancerous site. The composition comprises a pharmaceutically effective amount of collagen type III.

Claims (18)

1. A method of suppressing metastasis and local recurrence of a cancer in a subject comprising:

a) removing the cancer tumor from the subject; and

b) implanting a composition to the site of tumor removed;

wherein the composition comprises a pharmaceutically effective amount of collagen type III and,

wherein the cancer is breast cancer.

2. The method of claim 1 , wherein the subject is a human.

3. The method of claim 1 , wherein the collagen type III in the composition is in the range from about 1% to about 100% by weight.

4. The method of claim 1 , wherein the collagen type III in the composition is in the range from about 20% to about 80% by weight.

5. The method of claim 1 , wherein the collagen type III in the composition is in the range from about 40% to about 60% by weight.

6. The method of claim 1 , wherein the composition further comprises a biocompatible material.

7. The method of claim 6 , wherein the biocompatible material is selected from the group consisting of alginate-poly-(L-lysine), alginate-poly-(L-lysine)-alginate, alginate-poly-(L-lysine)-polyethyleneimine, chitosan-alginate, polyhydroxylethyl-methacrylate-methyl methacrylate, carbonylmethylcellulose, K-carrageenan, chitosan, agarose-polyethersulphone-hexadi-methirine-bromide, ethyl-cellulose, silica gels, hydrogel, (meth)acrylate-oligolactide-PEO-oligolactide-(meth)acrylate, poly(ethylene oxide) (PEO), poly(propylene glycol) (PPO), PEO-PPO-PEO copolymers, poly(phosphazene), poly(methacrylates), poly(N-vinylpyrrolidone), PL(G)A-15 PEO-PL(G)A copolymers, poly(ethylene imine), poly(ethyl glycol) diacrylate, polycaprolactone, and combinations thereof.

8. The method of claim 1 , wherein the composition comprises a pharmaceutically effective amount of collagen type III, polycaprolactone, and poly(ethylene oxide) (PEO).

9. The method of claim 8 , wherein the composition is prepared by electrospinning.

10. The method of claim 1 , wherein the composition is in a formulation selected from the group consisting of a viscous liquid, a solution, a suspension, a liposomal formulation, a gel, a jelly, a cream, a lotion, an ointment, a suppository, a foam, an aerosol spray, an aqueous suspension, an oily suspensions, an aqueous solution, an oily solution, an emulsion, an emulsion ointment, and combinations thereof.

11. The method of claim 1 , wherein the composition is formulated in a gel.

12. The method of claim 1 , wherein collagen type III contains a cysteine-rich (CR) domain.

13. The method of claim 1 , wherein collagen type III does not contain a cysteine-rich (CR) domain.

14. A method of suppressing metastasis and local recurrence of a cancer in a subject comprising administering a composition to the cancerous site, wherein the composition comprises a pharmaceutically effective a mount of collagen type III, wherein the cancer is breast cancer.

Assignments (1)
CONFIRMATORY LICENSE Recorded May 25, 2018
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046245/0816 →
Continuity (2)
Provisional Application 62105532 · Jan 20, 2015
Related Publication 20180015149A1 · Jan 18, 2018